/PRNewswire / DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate.
/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2022 and provided a corporate update..
/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after.
DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury.